Cyclacel Pharmaceuticals (CYCC) to Offer Common Stock

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) announced today that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by Cyclacel.

Cyclacel intends to use the net proceeds from this offering to support the Company’s growth strategy and for working capital and general corporate purposes, including research and development expenses, and capital expenditures.

Oppenheimer & Co. Inc. is acting as the sole book-running manager for the public offering.

You May Also Be Interested In

• AMC Entertainment prices $200M stock offering to redeem senior notes
• Zodiac Gold closes C$5.6M private placement for Todi drill program
• Definium Therapeutics plans $500M public share offering